Rare diseases
Investigational molecules
Locations
Study of Nivolumab for Patients with High-Risk Stage II Melanoma After Surgery
GermanyStudy on Nivolumab and Tisagenlecleucel for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia After Treatment Loss
FranceStudy of Nivolumab and Ipilimumab for Patients with Type B3 Thymoma and Thymic Carcinoma After Chemotherapy
BelgiumStudy on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer
The NetherlandsStudy on Nivolumab, Ipilimumab, and Bevacizumab for Patients with Non-Small Cell Lung Cancer Spread to the Brain
GermanyStudy of Sitravatinib and Nivolumab vs. Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Chemotherapy and Checkpoint Inhibitor Therapy
ItalyStudy of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer
FranceStudy of regorafenib and nivolumab with radiotherapy for patients with stage II-III rectal cancer before surgery
BelgiumStudy on Early Discontinuation of Nivolumab and Ipilimumab in Patients with Advanced Melanoma
The NetherlandsStudy of nivolumab alone or combined with ipilimumab for patients with advanced solid tumors (breast, gastric, pancreatic, lung, bladder, or ovarian cancer)
GermanyStudy on the Effects of AS01B, Ipilimumab, and Nivolumab in Patients with Advanced Melanoma
BelgiumStudy of Nivolumab for Children and Adults with Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma
DenmarkTell us about your condition – we search every trial in Europe and connect you with the right site.
